Clearmind Medicine (NASDAQ:CMND) Announces Earnings Results

Clearmind Medicine (NASDAQ:CMND) announced its quarterly earnings data on Monday. The company reported ($6.78) earnings per share (EPS) for the quarter, Zacks reports.

Clearmind Medicine Price Performance

CMND opened at $3.14 on Wednesday. The business has a 50 day simple moving average of $5.92 and a 200-day simple moving average of $15.64. The stock has a market capitalization of $3.20 million, a P/E ratio of -0.02 and a beta of 0.64. Clearmind Medicine has a 12 month low of $2.10 and a 12 month high of $524.00.

Insider Activity at Clearmind Medicine

In other news, major shareholder Financial Lp Hrt sold 225,191 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $0.12, for a total value of $27,022.92. Following the completion of the sale, the insider directly owned 1,838,075 shares of the company’s stock, valued at $220,569. This trade represents a 10.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.